

The effect of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW): an analysis of the Eurotransplant registry

Jacob D. de Boer MD^{1,2}, Agita Streliece MSc³, Marieke van Rosmalen MD¹, Erwin de Vries MSc¹, Dirk Ysebaert MD PhD⁴, Markus Guba MD PhD⁵, A.E. Braat MD PhD², Undine Samuel MD PhD¹

On behalf of the Eurotransplant Liver and Intestine Advisory Committee (ELIAC) and Organ Procurement Process Chain Committee (OPCC).

Affiliations

¹Medical Staff, ³ Biostatistical Department, ⁶ Medical Director, Eurotransplant International Foundation, Leiden, The Netherlands

²Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

⁴Department of Hepatobiliary, Transplantation and Endocrine Surgery, Antwerp University Hospital, University of Antwerp, Belgium

⁵Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany

Corresponding author

J.D. de Boer, MD

Medical Staff Eurotransplant

E-mail: jacob.deboer@eurotransplant.org

Reprints will not be available from the authors.

Running title: The effect of HTK and UW

Key words: Europe; Liver Transplantation: Outcome: Preservation fluid

Authorship

Study concept and design: Jacob de Boer (JdB) and Undine Samuel (US)

Acquisition of data: Marieke van Rosmalen (MvR) and Erwin de Vries (EV)

Statistical analysis: JdB, Agita Streliece (AS)

Analysis and interpretation of data: JdB, AS, EV, Andries Braat (AB).

Drafting of the manuscript: JdB, US, MvR, AB.

Critical revision of the manuscript: Markus Guba (MG), AB, US, Dirk Ysebaert (DY), MvR, EV.

Study supervision: AS, US.

Conflicts of interest

The authors of this manuscript have no conflict of interest to disclose.

Funding

The manuscript was not prepared by or funded in any part by a commercial organization. No financial support or grants were used for the preparation of this manuscript.

Abbreviations

DRM, donor recipient model

DCD, Donor after circulatory death

ELIAC, Eurotransplant Liver Intestine Advisory Committee

ENIS, Eurotransplant Network Information System

ELTR, European Liver Transplant Registry

ET, Eurotransplant

ET-DRI, Eurotransplant donor risk index

GGT, gamma glutamyl transpeptidase

IQR, interquartile range

MELD, model for end-stage liver disease

sRRI, simplified recipient risk index

Abstract

Background

Both UW and HTK are currently used in the Eurotransplant region for preservation of liver allografts. Previous studies on their effect have led to a lot of discussion. This study aims to compare the effect of HTK and UW on graft survival.

Methods

First liver transplantations in adult recipients (≥ 18 years) from 1.1.2007 until 31.12.2016 were included. Graft survival was compared for livers preserved with HTK and UW at 30 days, 1, 3 and 5-years. A multivariable analysis of risk factors on graft survival was performed and outcome was adjusted for important confounders.

Results

Of all 10,628 first liver transplantations, 8,176 (77%) and 2,452 (23%) were performed with livers preserved with HTK and UW, respectively. Kaplan-Meier curves showed significant differences in graft survival between HTK and UW at 30 days (89% vs. 93%, $p < 0.001$), 1-year (75% vs. 82%, $p < 0.001$), 3-years (67% vs. 72%, $p < 0.001$) and at 5-years (60% vs. 67%, $p < 0.001$). No significant differences in outcome were observed in separate analyses of Germany or non-German countries. In multivariable analysis, UW was associated with a decreased risk of graft loss at 30 days (HR 0.772, $p = 0.002$) and at 1 year (0.847 (0.757-0.947)). When adjusted for risk factors, no differences in long term outcome could be detected.

Conclusions

Because the use of preservation fluids is clustered geographically, differences in outcome by preservation fluids are strongly affected by regional differences in donor and recipient characteristics. When adjusted for risk factors, no differences in long-

term graft survival exist between transplantations performed with livers that are preserved with either HTK or UW.

Introduction

Ischemic injury sustained during organ preservation influences post-transplantation outcomes in an important way. Throughout the process of organ preservation, preservation fluids are used. In the donor, the liver is perfused with cold preservation fluid after cross-clamping of the aorta. It is then packed in a sterile bag filled with this same fluid in a box with ice after hepatectomy¹. In the transplant hospital, the organ is perfused prior to transplantation using the same preservation fluid. Almost all livers within Eurotransplant (ET) are preserved by this 'cold storage'. Other preservation techniques such as machine perfusion are currently only performed in an experimental way.

Several preservation fluids are used within the ET region although most countries use either University of Wisconsin solution (UW) or histidine-tryptophan-ketoglutarate solution (HTK)². The choice of preservation fluid is thought to be important for outcome and a difference in effect on outcome has often been studied. First studies on the topic could not detect significant differences in short and long term patient- and graft survival²⁻⁷(table 1). This might have been a result of the frequent single-center design and low numbers of included transplantations. A larger study by Stewart *et al.* showed HTK to be associated with a higher risk of early graft loss (<30 days) as compared to UW in the UNOS database⁸. It contributed to a gradual change to UW although some centers prefer HTK for the lower viscosity and lower costs.

More recent studies of Kaltenborn *et al.*⁹ and Adam *et al.*¹⁰ presented conflicting results on the issue. Kaltenborn showed only minimal differences between HTK and

UW while Adam *et al.* found HTK to be associated with a significant increased risk of long-term graft loss (at least up to five years) as compared to UW in the European Liver Transplant Registry(ELTR)¹⁰. Several remarks and concerns with the design of the study and its conclusions were placed by Nashan *et al.*¹¹. Most important concerns were with including living donation, insufficient risk adjustment and the overrepresentation of German livers in the HTK group. Germany uses HTK exclusively and it has a MELD based allocation combined with one of the lowest donor rates of Europe¹². The difference in long-term outcome that was attributed to HTK in this study might rather reflect inferior outcomes in general in Germany. In response, Adam *et al.* published an analysis without living donors and German centers and more recently, an analysis based on propensity score matching^{13,14}. This analysis matched patients on ABO compatibility, recipient ischemic time ≥ 6 hours, gender, study period (2003-2007 vs. 2008-2012), recipient age ≥ 60 years, donor age ≥ 55 years, whole liver, urgency of transplantation, hepatocellular carcinoma, recipient HIV status and centers performing more than 10 liver transplantations from living donors. Although an association between HTK and graft loss could be seen, we believe that inter-regional differences in donor, transplant and recipient characteristics were insufficiently taken into account.

This study aims to evaluate the effect of HTK and UW on short- and long term outcome after liver transplantation in the Eurotransplant region, with adequate adjustment for (regional) differences in donor, transplant and recipient factors.

Patients and methods

Data selection

All first transplantations from deceased donor livers performed in adult recipients (≥ 18 years) from January 1, 2007 until December 31, 2016 were included.

Transplantations with livers from donors after circulatory death (DCD) (n=771), split allografts (n=380) and allografts from donors outside of Eurotransplant were excluded. When information on the used preservation fluids was missing (n=160) or when preserved with other preservation fluids than HTK or UW fluid (Celsior n=18, Eurocollins=1, IGL-1 n=79 and other n=216) transplantations were also excluded as well as transplantations performed in patients with a high-urgency status (n=888), with a combination other than liver/kidney and transplantations performed in Göttingen¹⁵. Transplantations were categorized in either HTK or UW according to the preservation fluid that was used during procurement and subsequent transport. Follow-up data were obtained from the Eurotransplant Network Information System (ENIS) and Eurotransplant (ET) Liver Registry up to September 2017. All data were anonymized for transplant center and patient related data with exception of country. The study protocol was approved by the Eurotransplant Liver Intestine Advisory Committee (ELIAC) and no ethical statement was required according to European guidelines and Dutch law.

Data analysis

Laboratory values were converted to standardized units and in case of missing values $< 2\%$, median values were used; gamma-glutamyl-transpeptidase (GGT) 38 U/L (1.8%) and recipient body mass index (BMI) 25.8 (0%). The Eurotransplant-Donor Risk Index (ET-DRI)¹⁶ was calculated for all transplanted livers and the

simplified recipient risk index (sRRI)¹⁷ was calculated for all recipients based on most recent laboratory Model for End Stage Liver Disease (MELD) score before transplantation. With the ET-DRI and sRRI the Donor-recipient Model (DRM) was calculated for all transplantations¹⁸. Serum creatinin value was set at 4 mg/d therapy according to ET guidelines for patients receiving renal replacement, MELD score was rounded to the nearest whole value (range 6-40). Donor HCVAbs, donor HBCAbs, recipient HCVAbs, dialysis of the recipient prior to transplantation and a history of diabetes in the donor were considered negative if not tested or missing. Rescue allocation is a center-oriented allocation after patient-oriented allocation and is started for short allocation time or medical reasons. Clinical characteristics were summarized by median and 25% and 75% interquartile ranges (IQR) and number and percentage (N/%) for respectively continuous and categorical variables. Numerical and categorical factors between groups were compared using Kruskal-Wallis and Chi-square tests.

Outcome measures

Primary outcomes used in the analyses were 30 days, 1, 3 and 5-year non death-censored graft survival. Secondary outcomes were 30 days, 1,3 and 5-year patient survival (PS). Graft survival was defined as the time period between date of transplantation and date of re-transplantation or patient death. Patient survival was defined as the time period between date of transplantation and date of patient death. Outcome was analyzed by Kaplan Meier analysis and log-rank tests when stratified by preservation fluid category (HTK, UW). Results were also stratified for transplantation region and preservation fluid (Germany+HTK, Germany+UW and Non-Germany+HTK, Non-Germany+UW).

Risk factors

To identify risk factors associated with graft survival, multivariable analysis was performed in a Cox regression analysis (backward selection) for all transplantations and included factors described to be associated with graft survival^{16,18–20}. These factors included donor age, cause of death, sex, BMI, latest GGT, HBcAb, HCVAb, history of diabetes, Recipient age, sex, BMI, laboratory MELD score at transplantation, etiology of primary liver disease, liver/kidney combination, dialysis prior to transplantation, total ischemic time, rescue allocation, allocation region (local, regional, extra-regional) and year of transplantation (continuous). Graft survival was then adjusted for all risk factors associated with 5-years graft survival in Germany, non-German countries and all transplantations. A potential effect of preservation fluids in HCC patients or in livers with longer cold ischemic times was described in literature¹⁰. This potential relation was analyzed with Kaplan-Meier analysis and in a Cox-regression analysis when adjusted for risk factors.

For all analyses a Wald p-value of < 0.05 was considered significant. Survival analyses were performed using Kaplan-Meier survival models and multivariable analyses were performed using Cox regression models. All analyses were performed with SPSS (version 24.0).

Results

Within the study period, 10,628 first liver transplantations were included. Median donor age of all transplantations was 55 years old (IQR 45-67) and median donor BMI 26 (IQR 24-28). Cerebro-vascular accident was the most frequent cause of death (62%) followed by trauma (20%). Near half of donors was allocated extra-regionally (46%) and median ET-DRI was 1.84. Most recipients were male (70%) and had a median age 56 years old and median BMI of 25. Transplanted recipients had a median laboratory MELD score of 16 and a median match MELD score of 24. Alcoholic disease was most frequent primary diagnosis (27%) followed by malignant disease (25%) and other cirrhosis (14%). The majority of transplantations was performed in Germany (62%) followed by Belgium (12%) and Austria (10%). Median sRRI was 1.86 and median DRM was 2.77.

Preservation fluid category

Of all transplantations, 8,176 (77%) and 2,452 (23%) were performed with livers preserved with HTK and UW, respectively. The relative use of UW decreased from 36% in 2007 to 18% in 2016 while the use of HTK increased from 64% to 82% (figure 1). Within donor countries strong preference for either HTK or UW during procurement was seen. HTK is preferred in Hungary (100%), Germany (98%), Slovenia (97%) and Austria (84%) while UW is preferred in The Netherlands (98%), Croatia (83%), Belgium (73%) and, with very small numbers, Luxembourg (100%). Median donor age and BMI were significantly higher in the HTK group as compared to the UW group (56 vs. 55 years old, $p<0.001$) and (26 vs. 25, $p<0.001$), respectively. Cause of death of the donor was significantly different between both groups ($p<0.001$); less trauma (17% vs. 26%) and more often anoxia (13 vs. 3%)

were registered as cause death in the HTK group. Total ischemic times were longer in the HTK group in comparison to the UW group (8.6 vs. 7.3 hours) and HTK livers were more often accepted in rescue allocation (32 vs. 16%, $p<0.001$). The median ET-DRI was significantly higher in the HTK group (1.90 vs. 1.66, $p<0.001$).

Recipient age and BMI were not different in both the UW and HTK group with a median of 56 years old ($p=0.093$) and BMI of 26 ($p=0.390$), respectively. Although both groups had a similar median laboratory MELD score, the distribution was not equal ($p<0.001$). As compared to the UW group, the HTK group has a higher proportion of transplanted MELD 25-35 (14% vs. 13%) and MELD 35+ recipients (13% vs 6%). Also, the match MELD did vary between HTK and UW (25 vs. 22, $p<0.001$). Median sRRI showed only minor differences while the DRM was significantly higher in the HTK group 2.85 vs. 2.56 ($p<0.001$), data shown in table 2.

Outcome

For all transplantations, graft survival at 30 days, 1, 3 and 5-years was 90%, 77%, 68% and 62%, respectively. Graft survival was significantly better in the UW group as compared to HTK at 30 days (93% vs. 89%, $p<0.001$), 1-year (82% vs. 75%, $p<0.001$), 3-years (72% vs. 67%, $p<0.001$) and at 5-years (67% vs. 60%, $p<0.001$), as shown in figure 2a. Similar differences were found in patient survival (PS); transplantations with UW preserved livers showed better PS as compared to HTK at 30 days (95% vs. 93%, $p<0.001$), 1-year (86% vs. 79%, $p<0.001$), 3-years (78% vs. 71%, $p<0.001$) and at 5-years (72% vs. 65%, $p<0.001$), as shown in figure 2b. Within Germany, 6,174 transplantations were performed with HTK and 463 with UW. In non-German countries 2,029 and 1,989 transplantations were performed with HTK and UW preserved livers, respectively. Outcome stratified for transplantation region

(Germany/non-Germany) and preservation fluid (HTK/UW) showed significantly lower overall graft survival in Germany. Within both regions, a trend for a slightly higher graft survival on short-term was seen for UW preserved livers as compared to HTK livers. On long-term, HTK livers showed a trend towards better graft survival. This was observed in Germany at 30 days (HTK 87% vs. UW 88%), 1-year (HTK 72% vs. UW 73%), 3-years (HTK 64% vs. UW 64%) and at 5-years (HTK 57% vs UW 56%). In Non-Germany this was also observed at 30 days (HTK 93% vs. 94%), 1 year (HTK 83% vs. 84%), 3 years (HTK 76% vs. UW 74%) and at 5 years (70% vs. 70%) (data shown in figure 4). Differences in outcome within both regions were not statistically significant at any time point.

Risk factors

In multivariable analysis, donor age, total ischemic time, donor last GGT, a history of diabetes in the donor, allocation region, rescue, recipient age, sex, etiology of liver disease, dialysis prior to transplantation, laboratory MELD score and year of transplantation were associated with 5-year graft survival. An association between outcome and preservation fluids could only be detected on short-term. UW was associated with a decreased risk of graft loss at 30 days (HR 0.762, CI 0.643-0.902, $p=0.002$) and at 1 year (HR 0.835, CI 0.746-0.934, $p=0.002$), data are shown in table 3. When adjusted for all risk factors associated with 5-years graft survival, no difference could be detected between both preservation fluids in transplantations performed in Germany ($p=0.572$) (figure 4a) or Non-Germany ($p=0.522$) (figure 4b). In all transplantations, also no difference in long-term outcome could be shown (data are shown in figure 4c).

Risk groups

Of all transplantations, 3527 (33%) of patients had a registered HCC. Patients with HCC had lower graft survival when transplanted with a liver preserved with HTK (n=2,747) as compared to livers preserved with UW (n=780) at 30 days (90% vs. 93%, p=0.013) and at 1 year (77% vs. 81%, p=0.006). When adjusted for other risk factors, a potential effect of HTK or UW in HCC patients was not observed at 30 days (p=0.557) or at 1 year (p=0.424).

When transplantations were stratified according to the ELTR total ischemic times categories, three groups were identified; livers transplanted with ≤ 6 hours (n=2,700), 6-12 hours (n=6,231) and ≥ 12 hours (n=1,697) of cold ischemic time. Only in transplantations performed with livers with 6-12 hours of cold ischemic time a statistically significant difference between HTK and UW could be observed (60% vs. 69%, p<0.001) (data are shown in figure S1a-c). When adjusted for other risk factors, or when analyzed per region (Germany vs. non-Germany) this potential negative impact of HTK in livers with longer cold ischemic times was not observed (data are shown in figure S2-3a,b,c.).

Discussion

This study shows that HTK is used in the majority of organ transplantations within Eurotransplant. The use of HTK is increasing, in contrast to UW. Overall graft survival is lower for livers preserved with HTK, but these results are strongly affected by regional differences in donor, recipient and transplant characteristics. When adjusted for these risk factors, no difference between HTK and UW could be observed.

The issue of preservation fluids remains an important point of discussion in liver transplantation. While evidence is still considered non-conclusive, different preservation fluids are currently used. This study shows, that although UW is internationally considered the golden standard, the relative use of UW within ET is decreasing while the use of HTK is increasing. To compare the effect of both preservation fluids, we have tried to ensure a homogenous study population. We have excluded all pediatric recipients, those receiving living related livers, livers from DCD donors, split livers and transplantations in high-urgent patients. Even with these strict inclusion criteria, this study includes a sufficiently high number of transplantations to detect minor differences in outcome and to perform an adequate multivariable analysis. The unfavorable characteristics of the group of livers preserved with HTK are likely to have contributed to the inferior graft- and patient survival. We have therefore separated our analysis per region, and have adjusted outcome for risk factors to interpret the differences in graft- and patient survival. The high completeness for important data like total ischemic times and MELD score add to the reliability of our findings. Although performed with care, risk adjustment may

still not be sufficient as is inherent to the retrospective design. We considered graft survival as primary outcome and did not have information on biliary complications or early bile production. This is a potential limitation, because some studies found suggestions for more post-transplantation bile production and less biliary complications in livers that were preserved with HTK²¹. However, biliary complications will likely also affect graft-survival in the long run.

The presented results of inferior *unadjusted* graft survival between HTK and UW are in line with the previously published study by the ELTR¹⁰. The ELTR study attributed this inferior long-term outcome to the use of HTK. Interesting, because the risk of HTK on graft loss was one of the lowest of all risk factors and only just statistically significant (RR 1.1, p=0.02) in over 34,500 transplantations¹⁰. Based on our findings, differences in long-term outcome in particular, are more likely to reflect differences in donor, recipient and transplant risks than an effect of the preservation fluid itself. When these differences are adequately taken into account no statistically significant difference could be detected between HTK and UW. This finding is in accordance to other studies that could not show any significant differences between HTK and UW²⁻⁷. Although this could be a result of an inadequate power due to small numbers, also Kaltenborn *et al.*⁹ neither have shown a difference in risk between both fluids despite a sizeable dataset (summary in table 1). A slightly better *short term* graft survival in livers preserved with UW, as reported by Stewart *et al.*⁸, may be present according to the risk adjusted survival in non-German countries (figure 4b).

Some studies have also described a more pronounced effect of preservation fluids in several subgroups. This would affect livers from DCD donors⁸, livers with total

ischemic times >12 hours¹⁰, patients with a HCC¹⁰ and split liver allografts¹⁰. A potential difference in DCD donors and split procedures could not be analyzed because these were excluded in this study. Differences in the other mentioned subgroups (categorical total ischemic time groups, HCC recipients) were not confirmed in this study or did not persist when adjusted for other risk factors.

To correctly interpret differences in outcome between several preservation fluids, the hypothesized causative pathway is important. The mechanism through which HTK would be inferior is however, currently still unclear. It could be related to differences in composition and viscosity² which might lead to different effects in liver cell volume, efficiency of wash-out or to the presence of antioxidant agents^{22,23}. These effects would, in theory, especially affect short term graft survival.

The differences in donor, transplant and patient characteristics between HTK and UW are primarily a result of the national choice of preservation fluids. Germany, for example, used HTK in 97% of all procurements and in 93% of their transplantations (the difference is because of international exchange within Eurotransplant). When compared to all HTK transplantations in Eurotransplant, 75% of all HTK preserved livers are transplanted in Germany. A country that has been struggling with one of the lowest DBD donor rates in Europe¹² and has implemented a MELD based allocation system. Both are likely to impact post-transplantation outcome in a negative way (figure 3). Due to the low donation rates, limits for liver allografts have been stretched and liver grafts are in general of lower quality; higher donor age, lab values and BMI. Also, because of the shortage of grafts, the waiting list expands and recipients will only be able to receive an offer when their MELD-score raises²⁴.

For this reason, outcome was stratified for Germany versus all other countries. It is therefore interesting, that transplantations with HTK livers showed a trend for similar or better graft survival as compared to UW in both regions although this difference was not statistically significant. This statistical phenomenon where findings in subgroups are apparently contradictory to overall results is called a Simpson's paradox. It can exist when different sample sizes are compared of groups with different outcome. In this case, because of discrepancies in the use of preservation fluids between countries with different post-transplantation outcome. The latter affects outcome of UW livers in Germany: Germany almost exclusively uses HTK so livers perfused with UW are likely to originate from other ET-countries. This is the case for livers that were not accepted for transplantation in the donor country.

The significant differences in outcome within Eurotransplant are also observed when results from ET are compared to the US. The presented 1-year graft survival rates in non-German countries of about 83% are significantly lower than the approximately 90% 1-year graft survival for first liver transplantations in the US in 2016²⁵. We believe that a difference in liver quality between ET and the US attributes to this difference in outcome. This difference in donor quality was shown by Blok *et al.* in 2012²⁶ and is evident for donor age; about 66% of all livers used for a transplant in the US in 2016 were from donors younger than 50 years old²⁵ as compared to 36% in ET (median was 55 years old)²⁴. This might be a result of regulation on center outcome as is done in the US or by an assumed higher shortage of organs in ET. Regardless of the reason(s), the difference in donor quality shows that centers in ET have expanded their criteria for acceptable donors to increase the number of

patients that can be transplanted and to decrease waiting list mortality. This strategy, however, comes at the cost of slightly inferior post-transplantation outcome.

In deciding what preservation fluid to use, the experience of surgeon and center should be the most important consideration. Our results indicate that no significant difference exists between both preservation fluids. Other aspects, like the lower viscosity, which is often appreciated by clinicians and the lower costs associated with the use of HTK might then also be taken into account.

Conclusions

The use of preservation fluids differs significantly per country within the Eurotransplant region. HTK is being used in the majority of liver transplantations and its use is increasing, in contrast to the use of UW. This retrospective database analysis shows that differences in outcome by preservation fluids are caused by regional differences in donor, recipient and transplant characteristics. These differences, rather than the used preservation fluid, cause the difference in outcome. When adjusted for these risk factors retrospectively, no differences in graft survival exist between transplantations performed with livers that are preserved with either HTK or UW.

Acknowledgements

The authors thank the Eurotransplant Liver and Intestine Advisory Committee and Eurotransplant for their support in providing the data. We acknowledge the effort of all liver transplant centers for providing data to the Eurotransplant registry.

References

1. Eurotransplant international Foundation. Eurotransplant guidelines, chapter 9 - The Donor. https://www.eurotransplant.org/cms/index.php?page=et_manual. Published 2017. Accessed October 24, 2017.
2. Erhard J, Lange R, Scherer R, Kox WJ. Comparison of solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation A prospective , randomized study. 1994;177-181.
3. Meine MH, Zanotelli ML, Neumann J, et al. Randomized Clinical Assay for Hepatic Grafts Preservation With University of Wisconsin or Histidine-Tryptophan-Ketoglutarate Solutions in Liver Transplantation. *Transplant Proc.* 2006;38(6):1872-1875. doi:10.1016/j.transproceed.2006.06.071.
4. Mangus RS, Tector AJ, Agarwal A, Vianna R, Murdock P, Fridell JA. Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. *Liver Transplant.* 2006;12(2):226-230. doi:10.1002/lt.20552.
5. Avolio AW, Agnes S, Nure E, et al. Comparative Evaluation of Two Perfusion Solutions for Liver Preservation and Transplantation. 2006;1067:1066-1067. doi:10.1016/j.transproceed.2006.03.009.
6. Mangus RS, Fridell JA, Vianna RM, et al. Comparison of Histidine-Tryptophan-Ketoglutarate Solution and University of Wisconsin Solution in Extended Criteria Liver Donors Richard. *Liver Transplant.* 2008;14:365-373. doi:10.1002/lt.
7. Rayya F, Harms J, Martin AP, Bartels M, Hauss J, Fangmann J. Comparison of Histidine-Tryptophan-Ketoglutarate Solution and University of Wisconsin Solution in Adult Liver Transplantation. *Transplant Proc.* 2008;40(4):891-894. doi:10.1016/j.transproceed.2008.03.044.
8. Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL, Segev DL. Histidine – Tryptophan – Ketoglutarate (HTK) Is Associated with Reduced Graft Survival in Deceased Donor Livers , Especially Those Donated After Cardiac Death. 2009:286-293. doi:10.1111/j.1600-6143.2008.02478.x.
9. Kaltenborn A, Gwiasda J, Amelung V, et al. of Wisconsin preservation solution : a retrospective observational double-center trial. 2014:1-9.
10. Adam R, Delvart V, Karam V, et al. Compared Efficacy of Preservation Solutions in Liver Transplantation : A Long-Term Graft Outcome Study From the European Liver Transplant Registry. 2015:395-406. doi:10.1111/ajt.13060.
11. Nashan B, Spetzler V, Schemmer P, et al. Letter to the Editor Regarding “ Compared Efficacy of Preservation Solutions in Liver Transplantation : A Long-Term Graft Outcome Study From the European Liver Transplant Registry .” 2015:3272-3273. doi:10.1111/ajt.13513.
12. European Directorate for the Quality of Medicine (EDQM). 2016;21:1-65. https://www.edqm.eu/sites/default/files/newsletter_transplant_volume_21_september_2016.pdf.
13. Adam R, Delvart V, Karam V. Reply to letter regarding “compared efficacy of preservation solutions in liver transplantation: A long-term graft outcome study from the European Liver Transplant Registry.” *Am J Transplant.* 2015. doi:10.1111/ajt.13512.
14. Adam R, Cailliez V, Karam V. Evaluation of HTK Preservation Solutions in

- Liver Transplantation: A Long-Term Propensity-Based Analysis of Outcome From the European Liver Transplant Registry. *Am J Transplant*. 2017;17(2):585-586. doi:10.1111/ajt.14009.
15. DSO. Organ Donation and Transplantation in Germany 2012. *Annu Rep*. 2012.
 16. Braat AE, Blok JJ, Putter H, et al. The eurotransplant donor risk index in liver transplantation: ET-DRI. *Am J Transplant*. 2012;12(10):2789-2796. doi:10.1111/j.1600-6143.2012.04195.x.
 17. Blok JJ, Putter H, Rogiers X, et al. Combined Effect of Donor and Recipient Risk on Outcome After Liver Transplantation: Research of the Eurotransplant Database. *LIVER Transplant*. 2015;21(12):1486-1493. doi:10.1002/lt.24308.
 18. Blok JJ, Ringers J, Putter H, Rahmel AO, Rogiers X, Braat AE. The combination of ET-DRI and recipient risk factors is predictive of graft failure after liver transplantation within the Eurotransplant region. *Transpl Immunol*. 2014;31(4):257. doi:10.1016/j.trim.2014.11.208.
 19. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. *Am J Transplant*. 2006;6(4):783-790. doi:10.1111/j.1600-6143.2006.01242.x.
 20. Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are There Better Guidelines for Allocation in Liver Transplantation? *Ann Surg*. 2011;254(5):745-754. doi:10.1097/SLA.0b013e3182365081.
 21. Feng L, Zhao N, Yao X, et al. Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: A systematic review. *Liver Transplant*. 2007;13(8):1125-1136. doi:10.1002/lt.21208.
 22. Lee CY, Mangino MJ. Preservation methods for kidney and liver. *Organogenesis*. 2009;5(3):105-112. doi:10.4161/org.5.3.9582.
 23. Feng XN, Xu X, Zheng S Sen. Current status and perspective of liver preservation solutions. *Hepatobiliary Pancreat Dis Int*. 2006;5(4):490-494. doi:10.1213/ANE.0b013e3182147f6d.
 24. Eurotransplant International Foundation. *Annual Report 2016*. Eurotransplant International Foundation; 2016. www.eurotransplant.org.
 25. OPTN. No Title. 2018. <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>. Accessed April 11, 2018.
 26. Blok JJ, Braat AE, Adam R, et al. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. *Liver Transpl*. 2012;18(1):112-119. doi:10.1002/lt.22447.

Tables

Table 1. Studies on the use and effect of perfusion fluids in deceased donor liver transplantation

Author	Year	Journal	Short description	Perfusion fluid	No. patients	Graft survival						
						30 days	3 Months	6 Months	1y	3 y	5 y	Best
Adam <i>et al.</i> ¹⁰	2015	AJT	Retrospective study on the ELTR database	HTK	8696				77%	69%	64%	UW
				UW	24562				83%	75%	69%	
				CE	7756				82%	73%	68%	
				IGL	1855				82%	75%	68%	
Kaltenborn <i>et al.</i> ⁹	2014	BMC Gastroenterology	Double center, retrospective study	HTK	1838	No effect in 3 month graft survival, HTK beneficial on long term graft survival in univariate but not in multivariable analysis						HTK
				UW	1314							
Stewart <i>et al.</i> ⁸	2009	AJT	Retrospective study on the UNOS database	HTK	4755	HTK vs. UW, OR 1.2 (1.04-1.39, p<0.012) on early graft loss (<30 days) in multivariable analysis						UW
				UW	12673							
Rayya <i>et al.</i> ⁷⁷	2008	Transplant Proc.	Single center, retrospective study	HTK	69	90%			71%	71%		UW
				UW	68	90%			78%	75%		
Mangus <i>et al.</i> ⁶	2008	Liver Transplant.	Single center, retrospective study in ECD livers	HTK	204		89%		84%			HTK
				UW	231		88%		83%			
Meine <i>et al.</i> ³	2006	Transplant Proc.	Single center, randomized, prospective study	HTK	37	No significant differences in 2 years graft survival (death censored)						N/A
				UW	65							
Avolio <i>et al.</i> ⁵	2006	Transplant Proc.	Single center study	HTK	14			86%				
				UW	21			81%				
Mangus <i>et al.</i> ⁴	2006	Liver Transplant.	Single center, retrospective study	HTK	174	92%		86%	81%			UW
				UW	204	92%		86%	82%			
Erhard <i>et al.</i> ²	1994	Transplant Int.	Prospective, randomized study	HTK	30		87%			77%		HTK
				UW	30		80%			74%		

Table 2. Donor and recipient characteristics per perfusion fluid, n=10,826

	HTK Bretschneider (n=8,176)	UW (n=2,452)	HTK vs. UW
	(N (%)/Median (25%/75% percentile)	(N (%)/Median (25%/75% percentile)	p-value
Donor Factor			
Donor Age (y)	56 (45-67)	55 (43-65)	<0.001
Height (cm)	174 (165-180)	174 (167-180)	0.097
Weight (kg)	80 (70-90)	76 (68-85)	<0.001
BMI	26 (24-28)	25 (23-28)	<0.001
Last GGT (U/L)	43 (22-99)	31 (17-62)	<0.001
Sex (male)	4,445 (54)	1,366 (56)	0.241
Cause of death			
Anoxia	1,020 (13)	82 (3)	
Circulation	113 (1)	158 (6)	
CNS Tumor	44 (1)	19 (1)	<0.001
CVA/Stroke	5,129 (63)	1,484 (61)	
Trauma	1,426 (17)	648 (26)	
Other	443 (5)	61 (3)	
Diabetes (y)	816 (10)	173 (7)	<0.001
Transplant Factor			
Total ischemic time (h)	8.6 (6.3-11.0)	7.3 (5.0-9.6)	<0.001
Allocation region			
Local	1,980 (24)	1,004 (41)	
Regional	1,902 (23)	892 (36)	<0.001
Extra-regional	4,294 (53)	556 (23)	
Rescue (Yes)	2,613 (32)	389 (16)	<0.001
Country			
Germany	6,147 (75)	463 (19)	
Hungary	221 (3)	11 (0)	
Netherlands	124 (2)	465 (19)	
Belgium	476 (6)	752 (31)	<0.001
Croatia	196 (2)	593 (24)	
Slovenia	149 (2)	9 (0)	
Austria	863 (11)	159 (7)	
ET -DRI	1.90 (1.59 -2.24)	1.66 (1.40-1.92)	<0.001
Recipient Factor			
Age (y)	56 (49-62)	57 (49-62)	0.093
Height (cm)	174 (168-180)	173 (167-180)	0.003
Weight (kg)	80 (69-90)	78 (68-90)	0.019
BMI	26 (23-29)	26 (23-29)	0.390

Laboratory MELD	16 (11-27)	16 (11-23)	0.001
Match MELD	25 (16-31)	22 (17-27)	<0.001
Exceptional MELD (yes)	2753 (34)	790 (32)	0.181
Sex (male)	5,759 (70)	1696 (69)	0.228
Dialysis pre-transplant	1002 (12)	157 (6)	<0.001
Primary diagnosis			
Metabolic	264 (3)	91 (4)	
Acute	158 (7)	28 (1)	
Cholestatic	906 (10)	267 (11)	
Alcoholic	2,112 (24)	716 (29)	
Malignant	2,060 (24)	628 (26)	<0.001
HBV	316 (4)	94 (4)	
HCV	867(10)	211 (9)	
Other Cirrhosis	1,146 (13)	295 (12)	
Other	347 (5)	122 (5)	
LabMELD category			
<15	3,515 (43)	1040 (42)	
15-25	2,446 (30)	930 (38)	<0.001
25-35	1,136 (14)	329 (13)	
35+	1,079 (13)	153 (6)	
sRRI	1.87 (1.58-2.23)	1.86 (1.58-2.17)	<0.001
DRM	2.85 (2.31–3.51)	2.56 (2.09-3.08)	<0.001

Table 3. Multivariable analysis of factors associated with graft survival

	30 days		1 year		3 years		5 years	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Donor factor								
Preservation fluid (HTK) UW	0.762 (0.643-0.902)	0.002	0.835 (0.746-0.934)	0.002	*		*	
Age	*		1.007 (1.004-1.009)	<0.001	1.009 (1.006-1.011)	<0.001	1.009 (1.006-1.011)	<0.001
Total ischemic time (h)	1.031 (1.015-1.047)	<0.001	1.026 (1.015-1.037)	<0.001	1.017 (1.007-1.026)	0.001	1.016 (1.007-1.025)	0.001
Last GGT	1.001 (1.001-1.002)	<0.001	1.001 (1.000-1.001)	0.006	1.000 (1.000-1.001)	0.020	1.000 (1.000-1.001)	0.006
BMI	1.013 (1.000-1.027)	0.050	*		*		*	
Diabetes (no) yes	1.299 (1.076-1.570)	0.007	1.214 (1.065-1.385)	0.004	1.231 (1.097-1.382)	<0.001	1.207 (1.080-1.348)	0.001
Allocation (local)	*			0.039		0.003		0.001
Regional	*		1.077 (0.954-1.215)	0.230	1.078 (0.972-1.196)	0.154	1.074 (0.974-1.185)	0.151
Extra-regional	*		1.158 (1.033-1.297)	0.012	1.182 (1.072-1.303)	0.001	1.190 (1.085-1.305)	<0.001
Rescue (No) Yes	1.345 (1.159-1.560)	<0.001	1.212 (1.091-1.346)	<0.001	1.218 (1.113-1.332)	<0.001	1.219 (1.121-1.326)	<0.001
Recipient factor								
Age	*		1.011 (1.006-1.015)	<0.001	1.012 (1.007-1.016)	<0.001	1.011 (1.008-1.015)	<0.001
Sex (Female) Male	*		1.143 (1.040-1.256)	0.005	1.177 (1.083-1.280)	<0.001	1.183 (1.092-1.280)	<0.001
BMI	1.016 (1.003-1.029)	0.017	*		*		*	
Etiology (Metabolic)		0.002		0.005		<0.001		<0.001
Acute	1.897 (1.206-2.984)	0.006	1.389 (0.987-1.954)	0.059	1.372 (1.008-1.866)	0.044	1.398 (1.035-1.889)	0.029
Cholestatic	1.103 (0.751-1.622)	0.616	1.135 (0.871-1.480)	0.348	1.057 (0.836-1.336)	0.646	1.102 (0.877-1.383)	0.404
Alcoholic	0.918 (0.642-1.313)	0.641	0.990 (0.773-1.267)	0.935	0.926 (0.745-1.152)	0.491	0.990 (0.802-1.223)	0.928
Malignant	1.016 (0.704-1.466)	0.932	1.074 (0.832-1.385)	0.585	1.116 (0.894-1.394)	0.332	1.195 (0.964-1.481)	0.105
HBV	1.023 (0.653-1.602)	0.921	0.872 (0.634-1.201)	0.402	0.887 (0.672-1.171)	0.399	0.913 (0.698-1.194)	0.505
HCV	1.119 (0.764-1.640)	0.563	1.271 (0.978-1.652)	0.073	1.408 (1.120-1.769)	0.003	1.476 (1.183-1.843)	0.001
Other cirrhosis	0.943 (0.648-1.372)	0.758	1.010 (0.780-1.308)	0.940	1.002 (0.798-1.258)	0.986	1.052 (0.843-1.312)	0.655
Other/unknown	1.283 (0.816-2.016)	0.280	0.986 (0.706-1.378)	0.936	0.786 (0.581-1.062)	0.117	0.823 (0.616-1.098)	0.186
SLK (yes)	0.578 (0.371-0.901)	0.016	0.748 (0.567-0.986)	0.039	*		*	
Dialysis pre-transplant (no) yes	1.417 (1.153-1.742)	0.001	1.489 (1.296-1.709)	<0.001	1.231 (1.097-1.382)	<0.001	1.402 (1.246-1.578)	<0.001
LabMELD (<15)		<0.001		<0.001		<0.001		<0.001

		1.044 (0.889- 1.226)	0.59 8	1.083 (0.970- 1.209)	0.15 8	1.041 (0.947- 1.143)	0.40 5	1.042 (0.954- 1.138)	0.36 3
	>=15 and <25	1.356 (1.100- 1.671)	0.00 4	1.580 (1.374- 1.817)	<0.0 01	1.434 (1.268- 1.623)	<0.0 01	1.347 (1.196- 1.516)	<0.0 01
	>=25 and <35	1.776 (1.403- 2.248)	<0.0 01	1.976 (1.683- 2.320)	<0.0 01	1.799 (1.560- 2.075)	<0.0 01	1.705 (1.487- 1.956)	<0.0 01
	>=35								
Year of Transplantation (2007)		0.975 (0.954- 0.998)	0.03 0	0.979 (0.964- 0.995)	0.00 9	0.984 (0.970- 0.997)	0.98 4	0.985 (0.972- 0.999)	0.03 3

*No statistical significance and not in the equation.

The following factors were not statistically significantly associated with outcome at the measured time points: Donor sex, cause of death, HBcAb, HCVAb, Recipient sex, HCVAb




Figure 1. The use of HTK and UW in the Eurotransplant region

	2007		2008		2009		2010		2011		2012		2013		2014		2015		2016	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
HTK	665	64	762	71	806	77	880	75	858	74	929	84	799	79	856	79	843	84	778	82
UW	370	36	308	29	244	23	291	25	300	26	182	16	208	21	225	21	158	16	166	18

Figure 2a





Figure 2. Kaplan-Meier survival analysis by preservation fluid (n=10,628)

a. Graft survival

Preservation fluid category		30 days	1 year	3 year	5 year
HTK (n=8,176)	Survival	89%	75%	67%	60%
	N events	897	1,897	2,376	2,628
	N at risk	6,736	5,154	3,141	1,814
UW (n=2,452)	Survival	93%	82%	72%	67%
	N events	176	423	625	707
	N at risk	2,206	1,863	1,305	868
Log rank test UW vs. HTK		<0.001	<0.001	<0.001	<0.001

Figure 2b



b. Patient survival

Preservation fluid category		30 days	1 year	3 year	5 year
HTK (n=8,176)	Survival	93%	79%	71%	65%
	N events	547	1,554	2,023	2,273
	N at risk	7,086	5,443	3,360	1,955
UW (n=2,452)	Survival	95%	86%	78%	72%
	N events	113	341	509	595
	N at risk	2,269	1,939	1,397	935
Log rank test UW vs. HTK		<0.001	<0.001	<0.001	<0.001

Figure 3




Figure 3. Kaplan Meier survival analysis of graft survival by preservation fluid and transplant region (Germany vs. Non-Germany), (n=10,628)

Transplant region			30 days	1 year	3 years	5 years
Germany (n=6,610)	HTK n=6,147	Survival	87%	72%	64%	57%
		N events	764	1,577	1,959	2,165
		N at risk	4,927	3,764	2,399	1,420
	UW n=463	Survival	88%	73%	64%	56%
		N events	54	120	154	178
		N at risk	391	311	222	149
	Log rank test UW vs. HTK		0.444	0.707	0.814	0.944
Non-Germany (n=4,018)	HTK n= 2,029	Survival	93%	83%	76%	70%
		n events	133	320	417	463
		n at risk	1,809	1.390	742	394
	UW n= 1,989	Survival	94%	84%	74%	70%
		n events	122	303	471	529
		n at risk	1,815	1.552	1083	719
	Log rank test UW vs. HTK		0.462	0.365	0.488	0.779
HTK between regions		<0.001	<0.001	<0.001	<0.001	
UW between regions		<0.001	<0.001	<0.001	<0.001	

Figure 4a




Figure 4b




Figure 4c




Figure 4. Risk adjusted graft survival

- Germany adjusted for all separate risk factors
- Non-Germany adjusted for all separate risk factors
- All transplantations adjusted for all separate risk factors

Supplementary files

Figure 1Sa




Figure S1b




Figure S1c




Figure S1. Kaplan Meier survival analysis of graft survival per total ischemic time category (ELTR)

- Total ischemic time ≤ 6 hours, (n=2,700), p=0.175
- Total ischemic time 6-12 hours, (n=6,231), p=<0.001
- Total ischemic time ≥ 12 hours, (n=1,697), p=0.448

Figure S2a




Figure S2b




Figure S2c




Figure S2. Kaplan Meier survival analysis of graft survival per total ischemic time category (ELTR) – Germany

- a. Total ischemic time ≤ 6 hours, (n=1,010), p=0.369
- b. Total ischemic time 6-12 hours, (n=4,219), p=0.287
- c. Total ischemic time ≥ 12 hours, (n=1,381), p=0.207

Figure S3a




Figure S3b




Figure S3c




Figure S3. Kaplan Meier survival analysis of graft survival per total ischemic time category (ELTR) – Non-Germany

- a. Total ischemic time ≤ 6 hours, (n=1,690), p=0.539
- b. Total ischemic time 6-12 hours, (n=2,012), p=0.687
- c. Total ischemic time ≥ 12 hours, (n=316), p=0.549